Search

On November 3, 2021, a panel of MSK doctors joined The Abyssinian Baptist Church for an educational webinar about COVID-19 vaccination.

… Thursday, November 11, 2021 On November 3, 2021, a panel of MSK doctors joined Linda Thompson, leader of the Abyssinian Baptist Church’s Health Ministry, in an educational webinar to discuss questions about COVID-19 vaccination and address common myths and misconceptions about the vaccine. The panel

The FDA has approved an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.

… Friday, August 2, 2024 The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleucel (Tecelra ® , also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called  synovial sarcoma . Afami-cel is the first engineered

A new imaging approach could shorten the time needed to determine whether a brain tumor treatment is working.

… Friday, July 13, 2018 Summary It is hard to monitor whether treatment for a brain tumor is having an effect. A new diagnostic technique called hyperpolarized MRI provides a clear image of the brain’s metabolic activity. This can give important clues about whether a treatment is working in a shorter time

Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. Memorial Sloan Kettering experts are involved in notable research presented at the meeting and are available to comment on topics including immunotherapy, precision medicine and targeted treatments, genomics, cancer interception and prevention, clinical trial design, cancer health disparities, and more. For more information and to set up interviews or access photos and video, contact [email protected] and [email protected].

… Thursday, March 28, 2019 Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. This year’s theme, “ Integrative   Cancer Science • Global Impact • Individualized Patient Care ,“ reinforces

A small interfering RNA implant targeting KRAS G12D/G12V mutations has shown a promising trend toward improved overall survival and objective response rate in patients with locally advanced pancreatic cancer with these mutations, according to results of a multisite, international phase 2 clinical trial led by Memorial Sloan Kettering Cancer Center.

… Thursday, January 29, 2026 A small interfering RNA (siRNA) implant targeting KRAS G12D/G12V mutations has shown a promising trend toward improved overall survival (OS) and objective response rate (ORR) in patients with locally advanced pancreatic cancer (LAPC) with these mutations, according to results

Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering's new cancer research facility, including a 23-story laboratory structure that opens this month. Mr. Zuckerman's donation is the largest single commitment by an individual in Memorial Sloan Kettering's history.

… Wednesday, May 10, 2006 Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering’s new cancer research facility, including

A study from Memorial Sloan Kettering found that young patients ages 18 to 39 with early-onset cancer have an especially high risk of harboring inherited genetic (germline) mutations.

… Monday, June 22, 2020 A study from Memorial Sloan Kettering (MSK) found that young patients ages 18 to 39 with early-onset cancer have an especially high risk of harboring inherited genetic (germline) mutations. Results from this study were presented by Zsofia K. Stadler, MD , medical oncologist at MSK

MSK researchers are rethinking the relationship between metabolism and cancer, and finding insights in some unexpected places. Your beer glass, for example.

… Tuesday, January 12, 2016 Summary Scientists have known for 100 years that cancer cells metabolize nutrients in a unique way, though they haven’t understood why. In a new paper, MSK researchers reconsider the evidence and offer an unorthodox explanation, turning some commonsense wisdom on its head. Highlights

Memorial Sloan Kettering Cancer Center (MSK) researchers presented results of their latest research at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego from December 7 to 10, 2024.

… Tuesday, December 10, 2024 Memorial Sloan Kettering Cancer Center (MSK) researchers presented results of their latest research at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego from December 7 to 10, 2024. Highlights of practice-changing insights for patients

MSK’s new Robert and Kate Niehaus Center for Inherited Cancer Genomics is using the latest in gene sequencing technologies to discover the inherited causes of cancer.

… Tuesday, December 8, 2015 Summary MSK’s new Robert and Kate Niehaus Center for Inherited Cancer Genomics is using the latest in gene sequencing technologies to discover the inherited causes of cancer. The ultimate goal is to develop new approaches for prevention as well as earlier detection and treatment